Lexaria Bioscience Corp. (LEXX) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
The consensus price target is $1.50, representing an upside of 47.1% from the current price $1.02.
Analysts estimate Earnings Per Share (EPS) of $-0.44 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.47 vs est $-0.44 (missed -6.8%). 2025: actual $-0.66 vs est $-0.68 (beat +2.9%). Analyst accuracy: 95%.
LEXX Stock — 12-Month Price Forecast
$1.50
▲ +47.06% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for Lexaria Bioscience Corp., the price target is $1.50.
The average price target represents a +47.06% change from the last price of $1.02.
LEXX Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Lexaria Bioscience Corp. in the past 3 months
EPS Estimates — LEXX
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.47
vs Est –$0.44
▼ 6.4% off
2025
Actual –$0.66
vs Est –$0.68
▲ 3.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — LEXX
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.001B
▼ 7.7% off
2025
Actual $0.001B
vs Est $0.001B
▲ 5.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
